Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COV-AID: IL-1 and IL-6 Blockade in COVID-19
NCT04330638Phase 3Completed
- Sponsor
- Ghent University Hospital
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of anakinra, siltuximab, tocilizumab in coronavirus disease 2019 (COVID-19), cytokine release syndrome (CRS), sponsored by Ghent University Hospital. Started Apr 2020; status: completed.
02
Drugs
anakinrasiltuximabtocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT04330638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04330638.